Renovo is a privately held boutique pharmacetutical company specializing in the commercialization of pharmaceutical cocrystals. Renovo identifies new, patentable, solid forms of active pharmaceutical ingredients (APIs) that can significantly improve the physical properties of the API. Improved properties of cocrystals are being exploited to improve the bioavailability of poorly soluble APIs by incorporating high solubility cocrystals into supersaturating drug delivery systems. • Responsibilities at Renovo include planning, staffing, laboratory management and coordinating all scientific, accounting, legal and business development activities • Received an SBIR Phase I Grant from the National Science Foundationin 2013 to study the integration of highly soluble cocrystals into supersaturating drug delivery systems • Experienced with equipment automation and systems integration. Designed and implemented the automation of X-ray powder diffraction and Raman spectroscopy instruments to collect high-throughput data. This included performing in-house fabrication and modification of equipment using CNC machining equipment. • Designed and manufactured a complete high-throughput solid form screening platform based take-apart reactor blocks with integrated stirring and sonication capabilities. Crystallization conditions include wet or dry milling, slurry conversion, evaporation, and precipitation. • Mentored direct reports to increase their capabilities and expertise; all direct reports were able to directly leverage high value skills gained at Renovo in their subsequent industry positions • Negotiated a strategic partnership agreement to obtain an equity stake in an API contingent on reaching milestones in the development of bioavailability and stability improving formulations

Formed Triclinic Labs along with top level management from SSCI to continue the successful business strategy originated at SSCI. Triclinic Labs is a contract research organization specializing in solid-state pharmaceutical chemistry. Triclinic now has over 20 employees in a newly constructed facility. Approximately one third to one half of my time over the last six years has been allocated to Triclinic with the remainder allocated to Renovo. • Report directly to COO performing projects and reporting new R&D to be used in sales talks • Continuous R&D has maintained the leading role in cocrystals established at SSCI • Procured, directed and carried out client projects in crystal form screening and characterization

Amplio Pharma is an entrepreneurial startup funded by private capital that creates new intellectual property using cocrystal technology.

A faculty equivalent appointment in the Chemistry department (non-compensated) to facilitate academic collaborations both internal and external to Emory. Collaborations with ten researchers at eight institutions have resulted in thirteen academic publications in peer-reviewed journals.

The change in corporate culture and R&D priorities that followed the purchase of SSCI by Aptuit led to myself and the key top level management from SSCI leaving to start Triclinic. This consulting position was negotiated in order to smooth the transition. In this consulting role I completed projects, drafted patents and submitted research papers on behalf of Aptuit. Technology transfer related to the cocrystal program was completed.

Lead scientist at SSCI charged with investigating cocrystallization of pharmaceuticals in 2002 when the field was at it's infancy. ● From 2002 to 2008 SSCI became a leader in the field of pharmaceutical cocrystal under Dr. Childs' direction● Discovered a previously unknown class of cocrystals containing the hydrochloride salt of an API plus an additional non-ionized coformer● Lead scientist in the implementation and validation of a Symyx crystallization system for polymorph, salt and cocrystal screening● Developed successful hotstage (modified Kofler) techniques and designed and built customized equipment to perform the screening● Academic collaborations yielded significant advancements in screening approaches based on slurry transformation, wet milling, and phase-diagram directed solvent selection

Design Science was formed to pursue commercial applications based on cocrystals • Operations established at the EmTechBio start-up incubator facility at Emory University • Acquired in January, 2002, becoming a wholly-owned subsidiary of SSCI, Inc.